{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:18:57Z","timestamp":1786457937403,"version":"build-2736575974"},"reference-count":265,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR136097"],"award-info":[{"award-number":["NIHR136097"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n National Institute for Health and Care Excellence technology appraisals assess the effectiveness and cost-effectiveness of medicines at a single point in the treatment pathway. However, for some disease areas, such as non-small cell lung cancer, there are many recommendations, making it difficult to use National Institute for Health and Care Excellence guidance. The treatment pathway for metastatic stage 4 non-small cell lung cancer can be divided into decision points (nodes) based on histology (squamous or non-squamous), programmed death-ligand 1 expression, presence of tumour mutations and line of therapy. The National Institute for Health and Care Excellence commissioned this pilot to assess the potential of taking a \u2018pathways approach\u2019 to technology appraisals. The aim was to build a single disease-specific cost-effectiveness model for metastatic stage 4 non-small cell lung cancer patients not eligible for targeted therapies at first line, that can be updated with economic and clinical data as required.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a systematic review (searches last updated 11 July 2025) and network meta-analysis of treatment efficacy and safety at each decision node in the pathway. We used flexible fractional polynomial models for primary outcome progression-free survival, required for a model of treatment sequences.<\/jats:p>\n We built a novel cost-effectiveness model that compared sequences of treatments, and was populated using network meta-analyses for progression-free survival, data on overall survival after last-line therapy, evidence on treatment sequences from an analysis of systemic anticancer therapy data, and quality of life, cost and resource use estimates from previous technology appraisals. Drug list prices were used, but confidential discounts are available.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We included 15 randomised controlled trials and 1 single-arm study in the review, judged as some concerns or low risk of bias. Immunotherapies, in combination with doublet platinum chemotherapy, were most effective first-line treatments, although with higher adverse event rates. Immunotherapy monotherapies were most effective at second line, unless patients were suitable for targeted therapies.<\/jats:p>\n \n Sequences for non-squamous non-small cell lung cancer, programmed death-ligand 1 <\u200550%<\/jats:title>\n Sequences starting with atezolizumab\u2005+\u2005bevacizumab\u2005+\u2005doublet platinum chemotherapy had similar costs and quality-adjusted life-years to sequences starting with pembrolizumab\u2005+\u2005doublet platinum chemotherapy. Sequences starting with pemetrexed\u2005+\u2005platinum chemotherapy had the lowest costs but also the lowest total quality-adjusted life-years.<\/jats:p>\n <\/jats:sec>\n \n Sequences for non-squamous non-small cell lung cancer, programmed death-ligand 1 \u2265\u200550%<\/jats:title>\n Sequences starting with pembrolizumab\u2005+\u2005doublet platinum chemotherapy had highest quality-adjusted life-years, but higher costs compared to other sequences. Sequences starting with pemetrexed\u2005+\u2005platinum chemotherapy had the lowest cost and the lowest number of quality-adjusted life-years.<\/jats:p>\n <\/jats:sec>\n \n Sequences for squamous non-small cell lung cancer, programmed death-ligand 1 <\u200550%<\/jats:title>\n Sequences starting with pembrolizumab\u2005+\u2005doublet platinum chemotherapy had higher quality-adjusted life-years and higher costs than sequences starting with platinum chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Sequences for squamous non-small cell lung cancer, programmed death-ligand 1 \u2265\u200550%<\/jats:title>\n Sequences starting with atezolizumab had the highest predicted quality-adjusted life-year gains, slightly higher than for sequences starting with pembrolizumab. Sequences starting with platinum chemotherapy had the lowest quality-adjusted life-years, but the lowest total costs.<\/jats:p>\n Patients in the systemic anticancer therapy analysis had a shorter time on treatment than those in trials, resulting in lower treatment costs and causing the immunotherapy sequences to appear more cost effective.<\/jats:p>\n <\/jats:sec>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our model can be used to estimate either the most cost-effective sequence of treatments or the most cost-effective treatment at a given point in the pathway, although our results are based on drug list prices and these would need to be updated to draw conclusions about the relative cost-effectiveness of different treatment sequences. We were able to use real-world data from systemic anticancer therapy to estimate model parameters and sequences that reflect clinical practice. Our model can readily be updated and used as a reference model for metastatic non-small cell lung cancer.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n The study is registered as PROSPERO CRD42023470119.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136097) and is published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 30, No. 46. See the NIHR Funding and Awards website for further award information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/gjnw3422","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:03:16Z","timestamp":1745301796000},"page":"1-319","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-3749","authenticated-orcid":true,"given":"Hugo","family":"Pedder","sequence":"first","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8883-0167","authenticated-orcid":true,"given":"Catalina Lopez","family":"Manzano","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-7568","authenticated-orcid":true,"given":"Lindsay","family":"Claxton","sequence":"additional","affiliation":[{"name":"NICE Science, Evidence and Analytics Directorate, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5682","authenticated-orcid":true,"given":"Penny","family":"Whiting","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-6325","authenticated-orcid":true,"given":"Lucy","family":"Beggs","sequence":"additional","affiliation":[{"name":"NICE Science, Evidence and Analytics Directorate, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6565-0790","authenticated-orcid":true,"given":"Ayman","family":"Sadek","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7214-4563","authenticated-orcid":true,"given":"Kusal","family":"Lokuge","sequence":"additional","affiliation":[{"name":"NICE Science, Evidence and Analytics Directorate, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0969-602X","authenticated-orcid":true,"given":"Eve","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-5607","authenticated-orcid":true,"given":"Chris","family":"Cooper","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-9461","authenticated-orcid":true,"given":"Rachel","family":"James","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6578-8455","authenticated-orcid":true,"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"NICE Science, Evidence and Analytics Directorate, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3461-9691","authenticated-orcid":true,"given":"Robert","family":"Willans","sequence":"additional","affiliation":[{"name":"NICE Science, Evidence and Analytics Directorate, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-9631","authenticated-orcid":true,"given":"Laura","family":"Webster","sequence":"additional","affiliation":[{"name":"National Cancer Registration and Analysis Service (NCRAS), Public Health England, Didcot, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7006-0938","authenticated-orcid":true,"given":"Joe","family":"Carroll","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-7841","authenticated-orcid":true,"given":"David","family":"Phillippo","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6760-6946","authenticated-orcid":true,"given":"David","family":"Wonderling","sequence":"additional","affiliation":[{"name":"NICE Science, Evidence and Analytics Directorate, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-6842","authenticated-orcid":true,"given":"Adam","family":"Dangoor","sequence":"additional","affiliation":[{"name":"Bristol Cancer Institute, Bristol Haematology and Oncology Centre, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1781-4011","authenticated-orcid":true,"given":"Dharmisha","family":"Chauhan","sequence":"additional","affiliation":[{"name":"North Thames Genomic Medicine Service Alliance, Great Ormond Street Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0210-7069","authenticated-orcid":true,"given":"Stella","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Patient Representative, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-3205","authenticated-orcid":true,"given":"Nicky J","family":"Welton","sequence":"additional","affiliation":[{"name":"Bristol Technology Assessment Group (TAG), Bristol Medical School, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,6]]},"reference":[{"key":"key2026060516335600_ref1-bib1","volume-title":"Treatments for Non-small-Cell Lung Cancer (Analysis Plan)","author":"Welton","year":"2023"},{"key":"key2026060516335600_ref2-bib2","volume-title":"Taking a Proportionate Approach to Technology Appraisals","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026060516335600_ref3-bib3","volume-title":"Renal Cell Carcinoma Pathways Pilot (ID6186)","author":"National Institute for Health and Care Excellence","year":"n.d"},{"key":"key2026060516335600_ref4-bib4","volume-title":"(TA964) Cabozantinib with Nivolumab for Untreated Advanced Renal Cell Carcinoma","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"key2026060516335600_ref5-bib5","volume-title":"State of the Nation Report 2023","author":"National Lung Cancer Audit","year":"2023"},{"key":"key2026060516335600_ref6-bib6","volume-title":"Lung Cancer Mortality Statistics","author":"Cancer Research UK","year":"n.d"},{"key":"key2026060516335600_ref7-bib7","volume-title":"Implementing a Timed Lung Cancer Diagnostic Pathway","author":"NHS England","year":"2018"},{"key":"key2026060516335600_ref8-bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00359-2016","article-title":"Risk factors for lung cancer worldwide","volume":"48","author":"Malhotra","year":"2016","journal-title":"Eur Respir J"},{"key":"key2026060516335600_ref9-bib9","doi-asserted-by":"crossref","first-page":"102895","DOI":"10.1016\/j.critrevonc.2020.102895","article-title":"Lung cancer in never smokers: the role of different risk factors other than tobacco smoking","volume":"148","author":"Corrales","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"key2026060516335600_ref10-bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.202011-4063OC","article-title":"Air pollution, genetic factors, and the risk of lung cancer: a prospective study in the UK biobank","volume":"204","author":"Huang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"key2026060516335600_ref11-bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"key2026060516335600_ref12-bib12","volume-title":"National Optimal Lung Cancer Pathway","author":"Lung Clinical Expert Group","year":"2017"},{"key":"key2026060516335600_ref13-bib13","volume-title":"Lung Health Checks","author":"NHS","year":"2023"},{"key":"key2026060516335600_ref14-bib14","volume-title":"National Lung Cancer Audit. Spotlight Report on Molecular Testing in Advanced Lung Cancer","author":"Royal College of Physicians","year":"2020"},{"key":"key2026060516335600_ref15-bib15","volume-title":"Lung Cancer Statistics","author":"Cancer Research UK","year":"n.d"},{"key":"key2026060516335600_ref16-bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref17-bib17","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"key2026060516335600_ref18-bib18","volume-title":"NLCA Annual Report 2022","author":"Royal College of Physicians","year":"2022"},{"key":"key2026060516335600_ref19-bib19","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","article-title":"PD-L1 expression in lung cancer","volume":"11","author":"Yu","year":"2016","journal-title":"J Thorac Oncolo"},{"key":"key2026060516335600_ref20-bib20","doi-asserted-by":"crossref","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"key":"key2026060516335600_ref21-bib21","first-page":"415","article-title":"Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy","volume":"22","author":"Grodzka","year":"2023","journal-title":"EXCLI J"},{"key":"key2026060516335600_ref22-bib22","volume-title":"National Genomic Test Directory for Cancer","author":"NHS England","year":"2023"},{"key":"key2026060516335600_ref23-bib23","volume-title":"Treatments for Non-Small-Cell Lung Cancer: Final Scope","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026060516335600_ref24-bib24","volume-title":"(TA683) Pembrolizumab with Pemetrexed and Platinum Chemotherapy for Untreated, Metastatic, Non-squamous Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"key2026060516335600_ref25-bib25","volume-title":"(TA584) Atezolizumab in Combination for Treating Metastatic Non-squamous Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2026060516335600_ref26-bib26","volume-title":"(TA531) Pembrolizumab for Untreated PD-L1-Positive Metastatic Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2026060516335600_ref27-bib27","volume-title":"(TA770) Pembrolizumab with Carboplatin and Paclitaxel for Untreated Metastatic Squamous Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2026060516335600_ref28-bib28","volume-title":"CRD\u2019s Guidance for Undertaking Reviews in Health Care. Centre for Reviews and Dissemination","author":"Centre for Reviews and Dissemination (CRD)","year":"2009"},{"key":"key2026060516335600_ref29-bib29","volume-title":"NICE Health Technology Evaluations: The Manual","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026060516335600_ref30-bib30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key2026060516335600_ref31-bib31","volume-title":"NICE DSU Technical Support Document 18: Methods for Population-adjusted Indirect Comparisons in Submission to NICE","author":"Phillippo","year":"2016"},{"key":"key2026060516335600_ref32-bib32","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 64 (Updated October 2023)","author":"Lefebvre","year":"2023"},{"key":"key2026060516335600_ref33-bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.04.002","article-title":"Established search filters may miss studies when identifying randomized controlled trials","volume":"112","author":"Cooper","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"key2026060516335600_ref34-bib34","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"Dias","year":"2016"},{"key":"key2026060516335600_ref35-bib35","volume-title":"Deduplicator","author":"Bond University","year":"2023"},{"key":"key2026060516335600_ref36-bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key2026060516335600_ref37-bib37","doi-asserted-by":"crossref","first-page":"i4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2026060516335600_ref38-bib38","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"key2026060516335600_ref39-bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40273-020-00980-w","article-title":"Quantitative evidence synthesis methods for the assessment of the effectiveness of treatment sequences for clinical and economic decision making: a review and taxonomy of simplifying assumptions","volume":"39","author":"Lewis","year":"2021","journal-title":"PharmacoEconomics"},{"key":"key2026060516335600_ref40-bib40","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/j.jval.2018.09.2250","article-title":"PRM130 \u2013 open-source software for developing computationally efficient cost-effectiveness models to evaluate sequential treatment strategies in oncology","volume":"21","author":"Incerti","year":"2018","journal-title":"Value Health"},{"key":"key2026060516335600_ref41-bib41","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jval.2021.11.069","article-title":"P71 the development of a flexible and easy to tailor disease model to estimate the outcomes of treatment sequences in advanced melanoma by combining trial and real-world data","volume":"25","author":"de Groot","year":"2022","journal-title":"Value Health"},{"key":"key2026060516335600_ref42-bib42","doi-asserted-by":"crossref","first-page":"A617","DOI":"10.1016\/j.jval.2014.08.2182","article-title":"Treatment sequencing survival model for patients with multiple myeloma ineligible for stem cell transplantation (SCT)","volume":"17","author":"Heeg","year":"2014","journal-title":"Value Health"},{"key":"key2026060516335600_ref43-bib43","doi-asserted-by":"crossref","first-page":"A70","DOI":"10.1016\/j.jval.2014.03.408","article-title":"Simulation and comparison of progression-free survival (PFS) among patients with non-squamous non-small cell lung cancer (NSCLC) receiving sequential therapy","volume":"17","author":"Chouaid","year":"2014","journal-title":"Value Health"},{"key":"key2026060516335600_ref44-bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1185\/03007995.2016.1149056","article-title":"Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients","volume":"32","author":"Diaby","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"key2026060516335600_ref45-bib45","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40273-019-00827-z","article-title":"Developing open-source models for the US Health System: practical experiences and challenges to date with the open-source value project","volume":"37","author":"Jansen","year":"2019","journal-title":"PharmacoEconomics"},{"key":"key2026060516335600_ref46-bib46","doi-asserted-by":"crossref","first-page":"102468","DOI":"10.1016\/j.ctrv.2022.102468","article-title":"Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer","volume":"111","author":"Schettini","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"key2026060516335600_ref47-bib47","doi-asserted-by":"crossref","first-page":"e114264","DOI":"10.1371\/journal.pone.0114264","article-title":"Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies","volume":"9","author":"Heng","year":"2014","journal-title":"PLOS ONE"},{"key":"key2026060516335600_ref48-bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000338001","article-title":"A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma","volume":"82","author":"Stenner","year":"2012","journal-title":"Oncology"},{"key":"key2026060516335600_ref49-bib49","volume-title":"(CG131) Colorectal Cancer: Diagnosis and Management","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key2026060516335600_ref50-bib50","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref51-bib51","doi-asserted-by":"crossref","first-page":"xi","DOI":"10.3310\/hta12150","article-title":"The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation","volume":"12","author":"Hind","year":"2008","journal-title":"Health Technol Assess"},{"key":"key2026060516335600_ref52-bib52","volume-title":"A Description of the IVI-NSCLC Model v1.0","author":"Incerti","year":"2019"},{"key":"key2026060516335600_ref53-bib53","volume-title":"Network Meta-analysis for Comparative Effectiveness Research","author":"Dias","year":"2018"},{"key":"key2026060516335600_ref54-bib54","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2014"},{"key":"key2026060516335600_ref55-bib55","volume-title":"NICE DSU Technical Support Document 14: Undertaking Survival Analysis for Economic Evaluations Alongside Clinical Trials \u2013 Extrapolation with Patient-level Data","author":"Latimer","year":"2011"},{"key":"key2026060516335600_ref56-bib56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res Synth Methods"},{"key":"key2026060516335600_ref57-bib57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2307\/2986270","article-title":"Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling","volume":"43","author":"Royston","year":"1994","journal-title":"Appl Stat"},{"key":"key2026060516335600_ref58-bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"key2026060516335600_ref59-bib59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jrsm.1539","article-title":"A non-parametric approach for jointly combining evidence on progression free and overall survival time in network meta-analysis","volume":"13","author":"Daly","year":"2022","journal-title":"Res Synth Methods"},{"key":"key2026060516335600_ref60-bib60","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"key2026060516335600_ref61-bib61","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"2014"},{"key":"key2026060516335600_ref62-bib62","volume-title":"Bayesian Survival Analysis Using the rstanarm R Package","author":"Brilleman","year":"2020"},{"key":"key2026060516335600_ref63-bib63","volume-title":"multinma: Bayesian Network Meta-analysis of Individual and Aggregate Data","author":"Phillippo","year":"2024"},{"key":"key2026060516335600_ref64-bib64","volume-title":"survextrap: A Package for Flexible and Transparent Survival Extrapolation","author":"Jackson","year":"n.d"},{"key":"key2026060516335600_ref65-bib65","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"PharmacoEconomics"},{"key":"key2026060516335600_ref66-bib66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lungcan.2021.03.020","article-title":"Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+\/-bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison","volume":"155","author":"Halmos","year":"2021","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref67-bib67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-021-01292-z","article-title":"Classifying information-sharing methods","volume":"21","author":"Nikolaidis","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"key2026060516335600_ref69-bib69","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref70-bib70","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref71-bib71","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JTO.0000000000000366","article-title":"PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer","volume":"10","author":"Zinner","year":"2015","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref72-bib72","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cllc.2014.12.002","article-title":"Cisplatin\/pemetrexed followed by maintenance pemetrexed versus carboplatin\/paclitaxel\/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE phase III randomized trial","volume":"16","author":"Galetta","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"key2026060516335600_ref73-bib73","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ejca.2011.03.020","article-title":"A randomised phase II study of docetaxel\/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)","volume":"47","author":"Belvedere","year":"2011","journal-title":"Eur J Cancer"},{"key":"key2026060516335600_ref74-bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref75-bib75","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref76-bib76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study","volume":"13","author":"Reck","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref77-bib77","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref78-bib78","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref79-bib79","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref80-bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2018.05.005","article-title":"Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057","volume":"102","author":"Reck","year":"2018","journal-title":"Eur J Cancer"},{"key":"key2026060516335600_ref81-bib81","volume-title":"Study of BMS-936558 Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC","author":"Clinical trials for eudract_number:2012-002472-14","year":"2012"},{"key":"key2026060516335600_ref82-bib82","volume-title":"Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC","author":"NCT01673867","year":"2023"},{"key":"key2026060516335600_ref83-bib83","volume-title":"Study of BMS-936558 Compared to Docetaxel in Previously Treated Advanced or Metastatic Non-squamous NSCLC","author":"CN-01881089","year":"2012"},{"key":"key2026060516335600_ref84-bib84","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref85-bib85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2021.12.009","article-title":"Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer","volume":"165","author":"Chang","year":"2021","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref86-bib86","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2020.11.013","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)","volume":"152","author":"Chang","year":"2021","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref87-bib87","volume-title":"Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated with Advanced or Metastatic Non Small Cell Lung Cancer","author":"NCT02613507","year":"2015"},{"key":"key2026060516335600_ref88-bib88","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"key2026060516335600_ref89-bib89","volume-title":"Study to Compare AMG 510 \u2018Proposed INN Sotorasib\u2019 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200)","author":"NCT04303780","year":"2023"},{"key":"key2026060516335600_ref90-bib90","first-page":"S1348","article-title":"First-line pemetrexed plus cisplatin followed by maintenance pemetrexed vs carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced non squamous non-small cell lung cancer: a quality of life-oriented, multicenter randomized phase III trial of the goim (gruppo oncologico Italia meridionale)","volume":"8","author":"Galetta","year":"2013","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref91-bib91","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1200\/jco.2013.31.15_suppl.8071","article-title":"First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: A quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale)","volume":"31","author":"Galetta","year":"2013","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref92-bib92","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2012.43.6758","article-title":"Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial","volume":"30","author":"Ardizzoni","year":"2012","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref93-bib93","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref94-bib94","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref95-bib95","volume-title":"A Study of Atezolizumab (MPDL3280A) Compared with a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants with Stage IV Non-squamous or Squamous Non-small Cell Lung Cancer (NSCLC)","author":"NCT02409342","year":"2015"},{"key":"key2026060516335600_ref96-bib96","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/j.jtho.2016.09.091","article-title":"PS01.56: IMpower110: phase III trial comparing 1L atezolizumab with chemotherapy in PD-L1\u2013selected chemotherapy-naive NSCLC patients","volume":"11","author":"Herbst","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref97-bib97","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref98-bib98","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.19.03158","article-title":"Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer","volume":"38","author":"Reck","year":"2020","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref99-bib99","volume-title":"A Study of Atezolizumab in Combination with Carboplatin Plus (+) Paclitaxel with or without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab in Participants with Stage IV Non-squamous Non-small Cell Lung Cancer (NSCLC) (IMpower150)","author":"NCT02366143","year":"2021"},{"key":"key2026060516335600_ref100-bib100","doi-asserted-by":"crossref","first-page":"e003027","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key2026060516335600_ref101-bib101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Resp Med"},{"key":"key2026060516335600_ref102-bib102","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers13051176","article-title":"Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the impower150 trial","volume":"13","author":"Hopkins","year":"2021","journal-title":"Cancers"},{"key":"key2026060516335600_ref103-bib103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","article-title":"Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150","volume":"126","author":"Hopkins","year":"2022","journal-title":"Br J Cancer"},{"key":"key2026060516335600_ref104-bib104","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref105-bib105","volume-title":"A Clinical Phase III Study That Investigates the Efficacy of Atezolizumab in Combination with Carboplatin-Paclitaxel with or without Bevacizumab Compared with Carboplatin-Paclitaxel-Bevacizumab","author":"CN-01797305","year":"2015"},{"key":"key2026060516335600_ref106-bib106","volume-title":"A Phase III, Open-Label, Randomized Study of mpdl3280a (Anti-pd-l1 Antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy Na\u00efve Patients with Stage IV Non-squamous Non-small Cell Lung Cancer","author":"CN-01862749","year":"2015"},{"key":"key2026060516335600_ref107-bib107","doi-asserted-by":"crossref","first-page":"XI31","DOI":"10.1093\/annonc\/mdx760.002","article-title":"Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +\/\u2212 bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPOWER150)","volume":"28","author":"Reck","year":"2017","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref108-bib108","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref109-bib109","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","article-title":"Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer","volume":"6","author":"Scagliotti","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref110-bib110","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2006.06.7835","article-title":"Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer","volume":"24","author":"Weiss","year":"2006","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref111-bib111","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2012.10.015","article-title":"Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study","volume":"79","author":"Sun","year":"2013","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref112-bib112","first-page":"4631","article-title":"Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer","volume":"33","author":"Kawahara","year":"2013","journal-title":"Anticancer Res"},{"key":"key2026060516335600_ref113-bib113","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"key2026060516335600_ref114-bib114","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref115-bib115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref116-bib116","first-page":"56","article-title":"Overall survival with second-line pembrolizumab in patients with non-small-cell lung cancer: randomized phase III clinical trial versus propensity-adjusted real-world data","volume":"5","author":"Jemielita","year":"2021","journal-title":"JCO: Clin Cancer Inform"},{"key":"key2026060516335600_ref117-bib117","volume-title":"MK-3475 vs. Docetaxel in Second-line Non-small Cell Lung Cancer","author":"CN-01820076","year":"2013"},{"key":"key2026060516335600_ref118-bib118","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdy545","article-title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref119-bib119","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref120-bib120","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ijc.34532","article-title":"Caicun. KEYNOTE-033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC","volume":"153","author":"Ren","year":"2023","journal-title":"Int J Cancer"},{"key":"key2026060516335600_ref121-bib121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/annonc\/mdx671.055","article-title":"KEYNOTE-033: phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)","volume":"28","author":"Zhou","year":"2017","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref122-bib122","volume-title":"Study of Pembrolizumab versus Docetaxel in Participants Previously Treated for Non-small Cell Lung Cancer (MK-3475-033\/KEYNOTE-033)","author":"NCT02864394","year":"2023"},{"key":"key2026060516335600_ref123-bib123","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref124-bib124","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref125-bib125","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"key2026060516335600_ref126-bib126","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref127-bib127","volume-title":"Study of Pembrolizumab (MK-3475) Compared to Platinum-based Chemotherapies in Participants with Metastatic Non-small Cell Lung Cancer (MK-3475-024\/KEYNOTE-024)","author":"NCT02142738","year":"2022"},{"key":"key2026060516335600_ref128-bib128","doi-asserted-by":"crossref","first-page":"VI578","DOI":"10.1093\/annonc\/mdw435.40","article-title":"KEYNOTE-024: pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) >=50%","volume":"27","author":"Reck","year":"2016","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref129-bib129","doi-asserted-by":"crossref","first-page":"IX7","DOI":"10.1093\/annonc\/mdx619","article-title":"Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naive NSCLC","volume":"28","author":"Satouchi","year":"2017","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref130-bib130","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"key2026060516335600_ref131-bib131","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >= 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref132-bib132","volume-title":"OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Na\u00efve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042)","author":"CN-01815532","year":"2014"},{"key":"key2026060516335600_ref133-bib133","volume-title":"Study of Pembrolizumab (mk-3475) Compared to Platinum-based Chemotherapies in Participants with Metastatic Non-small Cell Lung Cancer (mk-3475-042\/keynote-042)","author":"CN-01838179","year":"2015"},{"key":"key2026060516335600_ref134-bib134","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/ijc.33399","article-title":"Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study","volume":"148","author":"Wu","year":"2021","journal-title":"Int J Cancer"},{"key":"key2026060516335600_ref135-bib135","doi-asserted-by":"crossref","first-page":"s142","DOI":"10.1016\/S1556-0864(16)30304-5","article-title":"195TiP: Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042","volume":"11","author":"Mok","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref136-bib136","volume-title":"Study of MK-3475 (Pembrolizumab) versus Platinum-based Chemotherapy for Participants with PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042\/KEYNOTE-042)","author":"NCT02220894","year":"2014"},{"key":"key2026060516335600_ref137-bib137","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref138-bib138","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref139-bib139","volume-title":"Study of Pemetrexed+Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in Participants with First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189\/KEYNOTE-189)","author":"NCT02578680","year":"2023"},{"key":"key2026060516335600_ref140-bib140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref141-bib141","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"key2026060516335600_ref142-bib142","doi-asserted-by":"crossref","first-page":"IX164","DOI":"10.1093\/annonc\/mdy425.042","article-title":"KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?","volume":"29","author":"Rodr\u00edguez-Abreu","year":"2018","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref143-bib143","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2021.02.021","article-title":"Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: a post hoc analysis of KEYNOTE-189","volume":"155","author":"Garon","year":"2021","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref144-bib144","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14980","article-title":"Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study","volume":"112","author":"Horinouchi","year":"2021","journal-title":"Cancer Sci"},{"key":"key2026060516335600_ref145-bib145","first-page":"100389","article-title":"Pemetrexed and platinum plus pembrolizumab in patients with metastatic nonsquamous NSCLC by tumor burden at baseline: a post hoc efficacy analysis of KEYNOTE-189","volume":"3","author":"Gadgeel","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"key2026060516335600_ref146-bib146","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/annonc\/mdz063.049","article-title":"Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study","volume":"30","author":"Horinouchi","year":"2019","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref147-bib147","volume-title":"Study of Pemetrexed+Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in Participants with First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189\/KEYNOTE-189)-Japan Extension Study","author":"NCT03950674","year":"2023"},{"key":"key2026060516335600_ref148-bib148","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref149-bib149","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref150-bib150","volume-title":"Phase III Study of Carboplatin and Paclitaxel or Nano Particle Albumin-Bound Paclitaxel (Nab-Paclitaxel) with or without Pembrolizumab in First Line Metastatic Squamous NSCLC","author":"CN-01864305","year":"2016"},{"key":"key2026060516335600_ref151-bib151","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref152-bib152","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1111\/cas.15816","article-title":"Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407","volume":"114","author":"Sugawara","year":"2023","journal-title":"Cancer Sci"},{"key":"key2026060516335600_ref153-bib153","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/JCO.19.01348","article-title":"Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer","volume":"38","author":"Mazieres","year":"2020","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref154-bib154","volume-title":"A Study of Carboplatin-Paclitaxel\/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in Adults with First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407\/KEYNOTE-407)","author":"NCT02775435","year":"2023"},{"key":"key2026060516335600_ref155-bib155","volume-title":"A Study of Carboplatin-Paclitaxel\/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in Adults with First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407\/KEYNOTE-407)-China Extension Study","author":"NCT03875092","year":"2023"},{"key":"key2026060516335600_ref156-bib156","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.pupt.2012.06.008","article-title":"Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients","volume":"25","author":"Li","year":"2012","journal-title":"Pulmon Pharmacol Therap"},{"key":"key2026060516335600_ref157-bib157","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref158-bib158","doi-asserted-by":"crossref","first-page":"100551","DOI":"10.1016\/j.esmoop.2022.100551","article-title":"External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer","volume":"7","author":"Rolfo","year":"2022","journal-title":"ESMO Open"},{"key":"key2026060516335600_ref159-bib159","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/onco.13976","article-title":"Patient-reported outcomes with selpercatinib among patients with RET fusion-positive non-small cell lung cancer in the phase I\/II LIBRETTO-001 trial","volume":"27","author":"Minchom","year":"2022","journal-title":"Oncologist"},{"key":"key2026060516335600_ref160-bib160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref161-bib161","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jtho.2022.02.004","article-title":"Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001","volume":"17","author":"McCoach","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref162-bib162","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key2026060516335600_ref163-bib163","volume-title":"A Phase 1\/2 Study of Oral Loxo-292 in Patients with Advanced Solid Tumors, Including RET-fusion Non-small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity","author":"jRCT2051220060","year":"2022"},{"key":"key2026060516335600_ref164-bib164","first-page":"669","article-title":"[Efficacy and safety analysis of selpercatinib in patients with RET fusion-positive non-small cell lung cancer: results from the Japanese subset of a global phase 1\/2 study]","volume":"49","author":"Nishio","year":"2022","journal-title":"Gan To Kagaku Ryoho"},{"key":"key2026060516335600_ref165-bib165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"key2026060516335600_ref166-bib166","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejca.2014.11.015","article-title":"Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer","volume":"51","author":"Novello","year":"2015","journal-title":"Eur J Cancer"},{"key":"key2026060516335600_ref167-bib167","volume-title":"LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer","author":"NCT00805194","year":"2018"},{"key":"key2026060516335600_ref168-bib168","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11523-017-0517-2","article-title":"Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study","volume":"12","author":"Gottfried","year":"2017","journal-title":"Target Oncol"},{"key":"key2026060516335600_ref169-bib169","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.lungcan.2015.08.003","article-title":"Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel","volume":"90","author":"Reck","year":"2015","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref170-bib170","first-page":"267","article-title":"Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D)","volume":"12","author":"Reck","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"key2026060516335600_ref171-bib171","volume-title":"Multicentre, Randomised, Double-Blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients with Stage IIIB\/IV or Recurrent Non Small Cell Lung Cancer after Failure of First Line Chemotherapy: BIBF 1120 Plus Docetaxel in 2nd Line NSCLC","author":"CN-01822806","year":"2008"},{"key":"key2026060516335600_ref172-bib172","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","article-title":"Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer","volume":"27","author":"Smit","year":"2009","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref173-bib173","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"key2026060516335600_ref174-bib174","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref175-bib175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref176-bib176","doi-asserted-by":"crossref","first-page":"P1906","DOI":"10.1016\/j.jtho.2018.08.2027","article-title":"Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study","volume":"13","author":"Gandara","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref177-bib177","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref178-bib178","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2018.11.020","article-title":"Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study","volume":"107","author":"von Pawel","year":"2019","journal-title":"Eur J Cancer"},{"key":"key2026060516335600_ref179-bib179","doi-asserted-by":"crossref","first-page":"VI581","DOI":"10.1093\/annonc\/mdw435.43","article-title":"Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L\/3L NSCLC","volume":"27","author":"Barlesi","year":"2016","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref180-bib180","doi-asserted-by":"crossref","first-page":"e001882","DOI":"10.1136\/jitc-2020-001882","article-title":"Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel","volume":"9","author":"Gandara","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key2026060516335600_ref181-bib181","doi-asserted-by":"crossref","first-page":"E405","DOI":"10.1016\/j.cllc.2018.01.004","article-title":"Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study","volume":"19","author":"Hida","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"key2026060516335600_ref182-bib182","volume-title":"A Study Comparing the Clinical Benefit and Side Effects of Atezolizumab to Docetaxel in Patients with Lung Cancer Who Have Not Benefited from Platinum-Containing Cancer Drugs","author":"CN-01862150","year":"2014"},{"key":"key2026060516335600_ref183-bib183","volume-title":"A Study of Atezolizumab Compared with Docetaxel in Participants with Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Failed Platinum-containing Therapy","author":"NCT02008227","year":"2013"},{"key":"key2026060516335600_ref184-bib184","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"key2026060516335600_ref185-bib185","volume-title":"Clinical Trial to Test the Efficacy and the Safety of MPDL3280A Compared with Docetaxel in Patients with Non-small Cell Lung Cancer","author":"CN-01849426","year":"2013"},{"key":"key2026060516335600_ref186-bib186","volume-title":"A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared with Docetaxel in Participants with Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Have Failed Platinum Therapy \u2013 \u2018POPLAR\u2019","author":"NCT01903993","year":"2013"},{"key":"key2026060516335600_ref187-bib187","article-title":"Safety and resource use in pronounce: a randomized, phase 3, open-label study of pemetrexed plus carboplatin with maintenance pemetrexed (PEMC) and paclitaxel plus carboplatin plus bevacizumab with maintenance bevacizumab (PCB) in patients with advanced non-squamous (NS) non-small-cell lung cancer (NSCLC)","volume":"8","author":"Ross","year":"2013","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref188-bib188","article-title":"Erratum: five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer (J Clin Oncol","volume":"39","author":"Anonymous","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref189-bib189","first-page":"181","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"12","author":"Giroux Leprieur","year":"2016","journal-title":"Breathe"},{"key":"key2026060516335600_ref190-bib190","volume-title":"Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)","author":"NCT01642004","year":"2012"},{"key":"key2026060516335600_ref191-bib191","volume-title":"An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)","author":"CN-01836025","year":"2013"},{"key":"key2026060516335600_ref192-bib192","volume-title":"An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)","author":"CN-01856830","year":"2013"},{"key":"key2026060516335600_ref193-bib193","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.cllc.2011.06.006","article-title":"Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE)","volume":"12","author":"Galetta","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"key2026060516335600_ref194-bib194","first-page":"S415","article-title":"Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials","volume":"6","author":"Tiseo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref195-bib195","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/jco.2011.29.15_suppl.7555","article-title":"Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): pooled analysis of two randomized trials","volume":"29","author":"Ardizzoni","year":"2011","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref196-bib196","first-page":"viii138","article-title":"Randomized phase II study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (GOIRC 02\/2006): preliminary results","volume":"21","author":"Tiseo","year":"2010","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref197-bib197","volume-title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) Compared with a Platinum (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine for PD L1-selected, Chemotherapy-naive Patients with Stage IV Non-squamous or Squamous Non-small Cell Lung Cancer","author":"EUCTR2014\u2010003083\u201021\u2010PL","year":"2015"},{"key":"key2026060516335600_ref198-bib198","volume-title":"Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-Line Treatment of Subjects with Advanced or Metastatic NSCLC without Actionable Genomic Alterations","author":"jRCT2061210074","year":"2022"},{"key":"key2026060516335600_ref199-bib199","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.22.02546","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"key":"key2026060516335600_ref200-bib200","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"key2026060516335600_ref201-bib201","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref202-bib202","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/ije\/dyz249","article-title":"Data resource profile: the systemic anti-cancer therapy (SACT) dataset","volume":"49","author":"Bright","year":"2019","journal-title":"Int J Epidemiol"},{"key":"key2026060516335600_ref203-bib203","volume-title":"NICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review","author":"Woods","year":"2017"},{"key":"key2026060516335600_ref204-bib204","volume-title":"[TA557] Pembrolizumab with Pemetrexed and Platinum Chemotherapy for Untreated, Metastatic, Non-squamous Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2026060516335600_ref205-bib205","volume-title":"[TA600] Pembrolizumab with Carboplatin and Paclitaxel for Untreated Metastatic Squamous Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2026060516335600_ref206-bib206","volume-title":"[TA447] Pembrolizumab for Untreated PD-L1-Positive Metastatic Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence"},{"key":"key2026060516335600_ref207-bib207","volume-title":"[TA705] Atezolizumab Monotherapy for Untreated Ddvanced Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"key2026060516335600_ref208-bib208","volume-title":"[TA428] Pembrolizumab for Treating PD-L1-positive Non-small-cell Lung Cancer after Chemotherapy","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"key2026060516335600_ref209-bib209","volume-title":"[TA520] Atezolizumab for Treating Locally Advanced or Metastatic Non-small-cell Lung Cancer after Chemotherapy","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2026060516335600_ref210-bib210","volume-title":"[TA713] Nivolumab for Advanced Non-squamous Non-small-cell Lung Cancer after Chemotherapy","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"key2026060516335600_ref211-bib211","volume-title":"[TA655] Nivolumab for Advanced Squamous Non-small-cell Lung Cancer after Chemotherapy","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key2026060516335600_ref212-bib212","volume-title":"[TA347] Nintedanib for Previously Treated Locally Advanced, Metastatic, or Locally Recurrent Non\u2011small\u2011cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2026060516335600_ref213-bib213","volume-title":"(TA724) Nivolumab with Ipilimumab and Chemotherapy for Untreated Metastatic Non-Small-Cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"key2026060516335600_ref214-bib214","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40273-021-01113-7","article-title":"Conceptual framework and methodological challenges for modeling effectiveness in oncology treatment sequence models","volume":"40","author":"Huang","year":"2022","journal-title":"PharmacoEconomics"},{"key":"key2026060516335600_ref215-bib215","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jval.2012.07.008","article-title":"Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework","volume":"15","author":"Tappenden","year":"2012","journal-title":"Value Health"},{"key":"key2026060516335600_ref216-bib216","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jval.2013.02.012","article-title":"Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model","volume":"16","author":"Tappenden","year":"2013","journal-title":"Value Health"},{"key":"key2026060516335600_ref217-bib217","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40273-016-0455-3","article-title":"Modeling treatment sequences in pharmacoeconomic models","volume":"35","author":"Zheng","year":"2017","journal-title":"PharmacoEconomics"},{"key":"key2026060516335600_ref218-bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17580","article-title":"Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project","volume":"17","author":"Lord","year":"2013","journal-title":"Health Technol Assess"},{"key":"key2026060516335600_ref219-bib219","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12571","article-title":"A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model","volume":"96","author":"Blommestein","year":"2016","journal-title":"Eur J Haematol"},{"key":"key2026060516335600_ref220-bib220","doi-asserted-by":"crossref","first-page":"e0291366","DOI":"10.1371\/journal.pone.0291366","article-title":"A systematic review of whole disease models for informing healthcare resource allocation decisions","volume":"18","author":"Jin","year":"2023","journal-title":"PLOS ONE"},{"key":"key2026060516335600_ref221-bib221","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"key2026060516335600_ref222-bib222","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40258-023-00792-x","article-title":"An investigation into the relationship between choice of model structure and how to adjust for subsequent therapies using a case study in oncology","volume":"21","author":"Cranmer","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"key2026060516335600_ref223-bib223","volume-title":"[TA855] Mobocertinib for Treating EGFR Exon 20 Insertion Mutation-positive Advanced Non-small-cell Lung Cancer after Platinum-based Chemotherapy","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026060516335600_ref224-bib224","volume-title":"[TA781] Sotorasib for Previously Treated KRAS G12C Mutation-positive Advanced Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2026060516335600_ref225-bib225","volume-title":"[TA760] Selpercatinib for Previously Treated RET Fusion-Positive Advanced Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2026060516335600_ref226-bib226","volume-title":"[TA911] Selpercatinib for Untreated RET Fusion-Positive Advanced Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026060516335600_ref227-bib227","volume-title":"[TA181] Pemetrexed for the First-line Treatment of Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2009"},{"key":"key2026060516335600_ref228-bib228","volume-title":"National Cancer Drugs Fund List","author":"NHS England","year":"2017"},{"key":"key2026060516335600_ref229-bib229","volume-title":"National Life Tables: UK","author":"Office for National Statistics","year":"2024"},{"key":"key2026060516335600_ref230-bib230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2019-0061","article-title":"First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment","volume":"11","author":"Velcheti","year":"2019","journal-title":"Immunotherapy"},{"key":"key2026060516335600_ref231-bib231","volume-title":"Health Technology Appraisal. Renal Cell Carcinoma Pathways Pilot. [ID6186] Committee Papers","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2026060516335600_ref232-bib232","volume-title":"National Cancer Drugs Fund List: Version 1.296","author":"National Cancer Drugs Fund List","year":"2024"},{"key":"key2026060516335600_ref233-bib233","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"key2026060516335600_ref234-bib234","volume-title":"[TA630] Larotrectinib for Treating NTRK Fusion-positive Solid Tumours","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key2026060516335600_ref235-bib235","volume-title":"[TA374] Erlotinib and Gefitinib for Treating Non-small-cell Lung Cancer That Has Progressed after Prior Chemotherapy","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2026060516335600_ref236-bib236","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref237-bib237","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"key2026060516335600_ref238-bib238","doi-asserted-by":"crossref","first-page":"A744","DOI":"10.1016\/j.jval.2016.09.2276","article-title":"Measurement of utilities by time to death related to advanced non-small cell lung cancer in South Korea","volume":"19","author":"Chang","year":"2016","journal-title":"Value Health"},{"key":"key2026060516335600_ref239-bib239","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/lmt-2016-0001","article-title":"Symptom burden in lung cancer: management updates","volume":"5","author":"Lehto","year":"2016","journal-title":"Lung Cancer Manag"},{"key":"key2026060516335600_ref240-bib240","volume-title":"[TA644] Entrectinib for Treating NTRK Fusion-positive Solid Tumours","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key2026060516335600_ref241-bib241","volume-title":"[TA403] Ramucirumab for Previously Treated Locally Advanced or Metastatic Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2026060516335600_ref242-bib242","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.lungcan.2008.03.019","article-title":"Health state utility scores in advanced non-small cell lung cancer","volume":"62","author":"Doyle","year":"2008","journal-title":"Lung Cancer"},{"key":"key2026060516335600_ref243-bib243","volume-title":"[TA192] Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key2026060516335600_ref244-bib244","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-7547-11-21","article-title":"A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries","volume":"11","author":"Mart\u00ed","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"key":"key2026060516335600_ref245-bib245","volume-title":"British National Formulary (BNF)","author":"National Institute for Health and Care Excellence","year":"2024"},{"key":"key2026060516335600_ref246-bib246","volume-title":"Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","author":"GOV.UK","year":"2023"},{"key":"key2026060516335600_ref247-bib247","volume-title":"National Lung Cancer Audit Annual Report 2017","author":"Royal College of Physicians","year":"2018"},{"key":"key2026060516335600_ref248-bib248","volume-title":"Carboplatin 10\u2009mg\/ml Intravenous Infusion","author":"emc","year":"n.d"},{"key":"key2026060516335600_ref249-bib249","volume-title":"National Cost Collection for the NHS","author":"NHS England","year":"n.d"},{"key":"key2026060516335600_ref250-bib250","volume-title":"Unit Costs of Health and Social Care Programme (2022\u20132027)","author":"Personal Social Services Research Unit","year":"2023"},{"key":"key2026060516335600_ref251-bib251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17060","article-title":"Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation","volume":"17","author":"Brown","year":"2013","journal-title":"Health Technol Assess"},{"key":"key2026060516335600_ref252-bib252","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/thx.2004.039479","article-title":"Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer","volume":"60","author":"Maslove","year":"2005","journal-title":"Thorax"},{"key":"key2026060516335600_ref253-bib253","volume-title":"National Cost Collection Data Publication 2021 - 2022","author":"NHS England"},{"key":"key2026060516335600_ref254-bib254","volume-title":"Understanding the cost of end of life care in different settings","author":"Marie Curie Cancer Care","year":"2012"},{"key":"key2026060516335600_ref255-bib255","volume-title":"[CG121] Lung Cancer: Diagnosis and Management","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"key2026060516335600_ref256-bib256","volume-title":"[TA411] Necitumumab for Untreated Advanced or Metastatic Squamous Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2026060516335600_ref257-bib257","volume-title":"[TA621] Osimertinib for Untreated EGFR Mutation-positive Non-small-cell Lung Cancer","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key2026060516335600_ref258-bib258","volume-title":"Appendix H: Appraisal Checklists, Evidence Tables, GRADE and Economic Profiles","author":"National Institute for Health and Care Excellence","year":"n.d"},{"key":"key2026060516335600_ref259-bib259","volume-title":"Study of Two Doses of Pembrolizumab (MK-3475) versus Docetaxel in Previously Treated Participants with Non-small Cell Lung Cancer (MK-3475-010\/KEYNOTE-010)","author":"NCT01905657","year":"2021"},{"key":"key2026060516335600_ref260-bib260","doi-asserted-by":"crossref","first-page":"i38","DOI":"10.1093\/annonc\/mdz063","article-title":"Final analysis of the phase III KEYNOTE-042 study: pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced\/metastatic NSCLC","volume":"30","author":"Mok","year":"2019","journal-title":"Ann Oncol"},{"key":"key2026060516335600_ref261-bib261","volume-title":"Study of Pembrolizumab (MK-3475) versus Platinum-based Chemotherapy for Participants with Programmed Cell Death-ligand 1 (PD-L1)-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042\/KEYNOTE-042)-China Extension Study","author":"NCT03850444","year":"2023"},{"key":"key2026060516335600_ref262-bib262","first-page":"100225","article-title":"Pembrolizumab plus chemotherapy for Chinese patients with metastatic squamous NSCLC in KEYNOTE-407","volume":"2","author":"Cheng","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"key2026060516335600_ref263-bib263","volume-title":"KEYNOTE-407: Study Protocol","author":"NCT02775435","year":"2023"},{"key":"key2026060516335600_ref264-bib264","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","article-title":"Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer","volume":"19","author":"Bordoni","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"key2026060516335600_ref265-bib265","article-title":"Erratum: updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (Journal of Thoracic Oncology (2018) 13(8) (1156\u20131170), (S1556086418306117) (10.1016\/j.jtho.2018.04.039))","volume":"13","author":"Anonymous","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key2026060516335600_ref266-bib266","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/1471-2407-10-633","article-title":"A randomized phase III study of the docetaxel\/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced\/metastatic non-small cell lung cancer","volume":"10","author":"Pallis","year":"2010","journal-title":"BMC Cancer"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJNW3422\/GJNW3422.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2051271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:10:58Z","timestamp":1780657858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJNW3422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":265,"alternative-id":["10.3310\/GJNW3422"],"URL":"https:\/\/doi.org\/10.3310\/gjnw3422","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"07-2023","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"11-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"07-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}